A new study from Hong Kong has shown that long-term prophylaxis (LTP) with garadacimab and lanadelumab led to significant reductions in attacks of hereditary angioedema (HAE) as well as an improvement in quality of life and overall treatment satisfaction.
The study, published in the Journal of Allergy and Clinical Immunology: Global, notes that there is currently no standard for LTP for HAE in many Asian countries, and this new data will hopefully help improve universal access to safe and effective treatment for these patients.
“This study clearly demonstrated the safety and effectiveness of LTP among HAE patients with frequent attacks, with significant improvement in clinical and psychological parameters, as well as work productivity and activity,” the authors wrote. “Although difficult to compare the two LTP medications given the small number of patients, the authors of this paper believe that garadacimab will be increasingly popular given the superior frequency of administration (every 4 weeks with garadacimab versus every 2 weeks with lanadelumab).”
The research team conducted a prospective study on 11 patients with HAE who experienced frequent attacks. Their baseline number of attacks was 2.5±1.3 per month, which, after 6 months of treatment, dropped to 0.1±0.1. Over 70% of the patients were attack free during this period, and none required hospitalization.
Read more about HAE therapies
Angioedema Quality of Life scores also improved, and reported activity impairment due to health declined. Patients also reported significant improvement in all dimensions of the Treatment Satisfaction for Medication questionnaire. No adverse events were observed.
The authors noted that the results should be interpreted with caution given the small sample size, but they highlighted the urgent need to make effective LTP with garadacimab and lanadelumab available for patients with HAE in Asian countries and beyond.
Wong JCY, Chiang V, Lam DLY, et al. Long-term prophylaxis for hereditary angioedema: initial experiences with garadacimab and lanadelumab. J Allergy Clin Immunol Glob. Published online August 30, 2023. doi:10.1016/j.jacig.2023.100166